Misako Nagasaka, MD, PhD recently shared insights on a comparative study between taletrectinib and crizotinib for TKI-naïve patients with ROS1-positive non-small cell lung cancer (NSCLC) at the European Lung Cancer Congress 2025 (ELCC).
Utilizing data from the TRUST-I (NCT04395677) and TRUST-II (NCT04919811) trials, the study revealed that taletrectinib not only achieved higher response rates but also significantly lowered the risk of disease progression and mortality compared to crizotinib. This promising advancement highlights the potential of taletrectinib in improving outcomes for patients with ROS1-positive NSCLC and has been published in the Journal of Thoracic Oncology.